Pivot, X.B., Bondarenko, I., Dvorkin, M., Trishkina, E., Ahn, J.-H., Im, S.-A., et al. (2017) A Randomized, Double-Blind, Phase III Study Comparing SB3 (Trastuzumab Biosimilar) with Originator Trastuzumab in Patients Treated by Neoadjuvant Therapy for HER2-Positive Early Breast Cancer. Journal of Clinical Oncology, 35, 509-509.

has been cited by the following article:

• TITLE: Biosimilars in Brazil: The Beginning of an Era of Broader Access

  AUTHORS: Marcio Debiasi, Franklin Fernandes Pimentel, Paula Juliana Seadi Pereira, Carlos H. Barrios

  KEYWORDS: Cancer Therapy, Biosimilar, Trastuzumab, Herceptin, Breast Cancer

  JOURNAL NAME: Journal of Cancer Therapy, Vol.8 No.9, September 12, 2017

  ABSTRACT: Cancer is a major public health issue worldwide, especially in the developing world where 70% of the cancer-related deaths occur. During the last three decades, with the advent of targeted therapies using monoclonal antibodies, patients’ survival and quality of life have dramatically improved. Unfortunately, these great accomplishments came at the expense of high financial costs which most of the population living in low-and middle-income countries cannot afford. Biosimilars (biotherapeutic products that are similar to an already licensed reference biotherapeutic product in terms of quality, safety and efficacy) have been successfully used in Europe and in US with a substantial reduction in price of around 30%. Brazil is about to have trastuzumab as the first biosimilar available to treat cancer patients in the country. Based on strict regulatory legislations, biosimilars are expected to deliver affordable yet effective and safe treatment options all over the world, expanding the access to cancer treatment and reducing inequalities.